Combined therapy with pirfenidone and nintedanib counteracts fibrotic silicosis in mice
In conclusion, pirfenidone and nintedanib, either individually or in combination, demonstrate substantial potential in advanced silicosis. Furthermore, combined therapy outperformed monotherapy, even at low doses. These therapeutic benefits are attributed to their influence on diverse signalling pathways and metabolic processes.
Authors
- Yiwei Shi (ORCID: https://orcid.org/0009-0008-7926-0871)
- Meiyue Song (ORCID: https://orcid.org/0000-0002-4475-1792)
- Junling Pang (ORCID: https://orcid.org/0000-0002-5866-311X)
- Jixin Wang (ORCID: https://orcid.org/0000-0001-9285-1002)
- Chen Wang (ORCID: https://orcid.org/0000-0002-3799-1165)
- Jing Wang (ORCID: https://orcid.org/0000-0003-2410-5408)
- Tiantian Zhang (ORCID: https://orcid.org/0000-0002-5162-0408)
- Wei Zeng (ORCID: https://orcid.org/0000-0001-7170-4003)
- Jiaxin Wang (ORCID: https://orcid.org/0000-0003-2119-5081)
- Xue Wang (ORCID: https://orcid.org/0000-0001-8577-1178)
- Shengxi Li
- Lu Bai (ORCID: https://orcid.org/0009-0002-9168-5465)
Institutions
- Harbin Medical University (CN)
- Shanxi Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- First Hospital of Shanxi Medical University (CN)
- Second Affiliated Hospital of Harbin Medical University (CN)
- Tsinghua University (CN)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2024-11-15
- DOI
- https://doi.org/10.1111/bph.17390
- Citations
- 3
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 1.26